

1,25-Dihydroxyvitamin D3 modulates the expression of a lymphokine (granulocyte-macrophage colony-stimulating factor) posttranscriptionally.

A Tobler, ... , A W Norman, H P Koeffler

J Clin Invest. 1988;**81**(6):1819-1823. <https://doi.org/10.1172/JCI113525>.

Research Article

We recently showed that 1,25(OH)₂D₃ sensitively inhibited the expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) in normal human mitogen-activated peripheral blood lymphocytes and in the human T lymphotropic virus I immortalized T cell line known as S-LB1 at the levels of both mRNA and protein. Using S-LB1 cells as a model system the present paper identifies at least in part the mechanisms by which 1,25(OH)₂D₃ regulates the expression of GM-CSF. Time-course studies demonstrated that by 6 and 48 h of exposure of S-LB1 cells to 1,25(OH)₂D₃ (10⁻⁸ M) the GM-CSF mRNA levels were reduced by 50 and 90%, respectively. Studies using cycloheximide as a protein synthesis inhibitor showed that the inhibitory action of 1,25(OH)₂D₃ on GM-CSF expression was dependent on new protein synthesis. In vitro nuclear run-on assays demonstrated that 1,25(OH)₂D₃ (10⁻⁸ M) did not change the rate of transcription of the GM-CSF gene. The t_{1/2} of GM-CSF mRNA, however, was profoundly reduced by 1,25(OH)₂D₃ when transcription was blocked by actinomycin D compared with the half-life of GM-CSF in the presence of actinomycin D alone (t_{1/2}, less than 0.5 and 4 h, respectively). Taken together, these results demonstrate that 1,25(OH)₂D₃ regulates expression of the lymphokine GM-CSF posttranscriptionally by influencing the stability of GM-CSF mRNA.

Find the latest version:

<https://jci.me/113525/pdf>



1,25-Dihydroxyvitamin D₃ Modulates the Expression of a Lymphokine (Granulocyte-Macrophage Colony-stimulating Factor) Posttranscriptionally

A. Tobler, C. W. Miller, A. W. Norman,* and H. P. Koeffler

Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, Los Angeles, California 90024; and *Department of Biochemistry, University of California, Riverside, California 92502

Abstract

We recently showed that 1,25(OH)₂D₃ sensitively inhibited the expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) in normal human mitogen-activated peripheral blood lymphocytes and in the human T lymphotropic virus 1 immortalized T cell line known as S-LB1 at the levels of both mRNA and protein. Using S-LB1 cells as a model system the present paper identifies at least in part the mechanisms by which 1,25(OH)₂D₃ regulates the expression of GM-CSF. Time-course studies demonstrated that by 6 and 48 h of exposure of S-LB1 cells to 1,25(OH)₂D₃ (10⁻⁸ M) the GM-CSF mRNA levels were reduced by 50 and 90%, respectively. Studies using cycloheximide as a protein synthesis inhibitor showed that the inhibitory action of 1,25(OH)₂D₃ on GM-CSF expression was dependent on new protein synthesis. In vitro nuclear run-on assays demonstrated that 1,25(OH)₂D₃ (10⁻⁸ M) did not change the rate of transcription of the GM-CSF gene. The *t*_{1/2} of GM-CSF mRNA, however, was profoundly reduced by 1,25(OH)₂D₃ when transcription was blocked by actinomycin D compared with the half-life of GM-CSF in the presence of actinomycin D alone (*t*_{1/2}, < 0.5 and 4 h, respectively). Taken together, these results demonstrate that 1,25(OH)₂D₃ regulates expression of the lymphokine GM-CSF posttranscriptionally by influencing the stability of GM-CSF mRNA.

Introduction

Survival, proliferation, and differentiation of hematopoietic cells are dependent on colony-stimulating factors (CSF).¹ The granulocyte-macrophage (GM) CSF is produced by activated T lymphocytes and by mesenchymal cells stimulated by macrophage-derived tumor necrosis factor alpha and IL-1 (1-4). The natural and recombinant GM-CSF possess multilineage CSA, and also enhance mature cell function of neutrophils, macrophages, and eosinophils (5-8).

Address all correspondence to Dr. Andreas Tobler, UCLA School of Medicine, Division of Hematology/Oncology, Factor Building 11-240, Los Angeles, CA 90024.

Received for publication 11 May 1987 and in revised form 9 November 1987.

1. *Abbreviations used in this paper:* GM-CSF, granulocyte-macrophage colony-stimulating factor; HTLV-1, human T cell lymphotropic virus-1; SSC, standard saline citrate; [α -³²P]UTP, [α -³²P]uridine-5'-triphosphate.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/88/06/1819/05 \$2.00

Volume 81, June 1988, 1819-1823

The hormonally active metabolite of vitamin D₃, 1,25(OH)₂D₃, may play an important role as an immunohematopoietic regulatory hormone (9, 10). We and others have shown that activated macrophages synthesized hormonally active 1,25(OH)₂D₃ (11, 12). Further, 1,25(OH)₂D₃ sensitively and specifically inhibited GM-CSF mRNA in normal mitogen-activated T lymphocytes and in a human T cell lymphotropic virus 1 (HTLV-1) immortalized T lymphocyte line derived from a normal individual (S-LB1) (13).

The present study addresses the mechanism by which 1,25(OH)₂D₃ controls expression of GM-CSF in human lymphocytes. Both transcriptional and posttranscriptional mechanisms control the regulation of gene expression in eukaryotic cells (14). For instance, studies showed that gamma-IFN regulated the expression of *c-myc* in the human lymphoblastic Daudi cells at the posttranscriptional level (15, 16). In contrast, a block to elongation of transcription was found to be responsible for the decreased expression of *c-myc* in the HL-60 promyelocytic leukemic cells when induced to differentiate by all-*trans* retinoic acid (17). We and others recently found that recombinant human tumor necrosis factor alpha regulated the expression of *c-myc* in the promyelocytic leukemia HL-60 cells and in HeLa cells at the level of transcription (18-20).

Using S-LB1 cells as a model system we show in this study that the reduced expression of GM-CSF, which is mediated by 1,25(OH)₂D₃ in T lymphocytes, is due to decreased stability of GM-CSF mRNA (posttranscriptional regulation).

Methods

Cell cultures and chemicals. The HTLV-1 immortalized T lymphocyte line S-LB1 (21) was maintained in suspension culture T-flask (Miles Laboratories, Inc., Naperville, IL) containing alpha medium (Flow Laboratories, Inc., Rockville, MD) and 10% fetal bovine serum (Irvine Scientific, Santa Ana, CA) in a humidified atmosphere of 7% CO₂. The 1,25(OH)₂D₃ was dissolved in 100% ethanol to a stock concentration of 1 × 10⁻³ M and stored at -20°C. The final concentration of 10⁻⁸ M was obtained by diluting the stock solution in PBS. Actinomycin D (Boehringer Mannheim Diagnostics, Inc., Indianapolis, IN) was dissolved in 100% ethanol to a stock concentration of 1 mg/ml. Cycloheximide was purchased from Sigma Chemical Co. (St. Louis, MO). Cell viability was not affected in the various experimental protocols, as determined by trypan blue exclusion.

S-LB1 cells were exposed to either actinomycin D (5 µg/ml), cycloheximide (20 µg/ml), or control alpha medium with 10% fetal bovine serum. The RNA synthesis was studied by labeling S-LB1 cells (1 × 10⁶/ml) with 0.5 µCi [¹⁴C] uridine for 1 h at 37°C (triplicate wells per point), washing the cells twice in PBS, precipitating the cells on ice with 5% TCA for 10 min, washing twice with 5% TCA, and heating for 60 min at 80°C. A 200-µl aliquot from each sample was mixed with Aquasol (New England Nuclear, Boston, MA) and counted in a scintillation photometer. Protein synthesis was determined by suspending the cells (75,000 cells/microtiter well) in methionine-free Earle's medium (Gibco, Grand Island, NY) with 5% FCS, and by exposing them

to 1 μ Ci [35 S] methionine for 90 min. The cells were harvested with a MASH-harvester, and isotope uptake was determined with liquid scintillation photometry (S1800; Beckman Instruments, Inc., Fullerton, CA).

DNA. The GM-CSF cDNA probe (0.9 kb, Eco RI-Bam HI) was derived from plasmid pCSF-2 (reference 2, a generous gift of S. Clark, Genetics Institute, Boston), the p53 probe (Hind III-Eco RI, 1.76 kb) from plasmid pR4-2 (22), the β -actin DNA (Eco RI-Bam HI, 700 bp) from plasmid pHF β A-3' ut (23), and the β -globin DNA (Bam HI, 1.8 kb) from plasmid p β 4.4 (24). The IL-2 receptor cDNA was kindly provided by T. Nikaido (Aichi Cancer Center Research Institute, Nagoya, Japan). When used as probes, the DNA inserts were oligolabeled (random primed) as described (25).

RNA blot technique. For cytoplasmic RNA, freshly harvested cells were suspended in hypotonic buffer (10 mM Tris-HCl [pH 7.4], 1 mM KCl, and 3 mM MgCl₂), and were lysed with 0.3% NP-40. Nuclei were removed by centrifugation. Cytoplasmic RNA was extracted by the phenol-chloroform method as essentially described (26) and quantified by absorbance at 260 nm. RNA blotting was performed essentially as described (27). Samples were denatured at 65°C for 10 min, size-separated by an agarose formaldehyde gel (1% agarose [Bethesda Research Laboratories, Gaithersburg, MD], 50 mM Na acetate, 10 mM Na₂ EDTA, 200 mM 3-(4-morpholino) propane sulfonic acid, and 2.2 M formaldehyde), and transferred to nylon membrane filters (ICN Biomedicals Inc., Irvine, CA). Filters were dried, baked at 80°C in vacuo for 2 h, and then prehybridized for 16–24 h. Hybridizations with 32 P-labeled DNA (1×10^6 cpm/ml) were performed at 42°C for 16–24 h in a solution containing 50% (vol/vol) formamide, 2 $\times$ standard saline citrate (SSC) ($1 \times$ SSC is 150 mM NaCl and 15 mM sodium citrate), 5 $\times$ Denhardt's (1 $\times$ Denhardt's is 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% BSA), 0.1% SDS, 1 mM EDTA, 10% (vol/vol), dextran sulfate (Sigma Chemical Co.) (500,000 mol wt), and 100 μ g/ml salmon sperm DNA (Sigma Chemical Co.). Filters were washed to a stringency of 0.1 $\times$ SSC, 1% SDS at 65°C, and exposed for 24–48 h at –70°C on Kodak XAR-5 film. Intensity of bands of hybridization were determined on autoradiograms exposed for various durations using a laser densitometer.

In vitro nuclear run-on assay. For run-on experiments, nuclei were isolated by resuspending the cells in hypotonic buffer (10 mM Tris-HCl [pH 7.4], 1 mM KCl, 3 mM MgCl₂) and lysing the cells with 0.3% NP-40. The nuclei were washed twice in hypotonic buffer, resuspended in nuclear storage buffer (40% glycerol, 50 mM Tris-HCl [pH 8.3], 5 mM MgCl₂, and 0.1 mM EDTA), and stored at –70°C. Transcription of nuclei and RNA isolation were performed as described (28). Briefly, the nuclei (1×10^8) were thawed and incubated for 10 min at 26°C in reaction buffer containing 200 μ Ci [α - 32 P]uridine-5'-triphosphate ([α - 32 P]UTP, 3,000 Ci/mmol) (ICN Biomedicals Inc.), and the labeled RNA was hybridized for 3 d to Southern blots of restriction enzyme digests of the various clones. The blots were washed to a final stringency of 0.1 $\times$ SSC, 0.1% SDS, and washed again at room temperature for 30 min in RNase (10 μ g/ml, in 2 $\times$ SSC). The filters were washed again at room temperature for 15 min in 2 $\times$ SSC.

Results

1,25(OH)₂D₃ regulates mRNA levels of GM-CSF in S-LB1 cells (Fig. 1). Exposure of S-LB1 cells for various lengths of time (0.5–48 h) to 1,25(OH)₂D₃ (10^{-8} M) showed a time-dependent decrease in the levels of GM-CSF mRNA (Fig. 1, top). A 48-h exposure resulted in an $\sim$ 90% reduction of GM-CSF mRNA levels (lane 6) compared with the untreated control sample (lane 1); and a 50% reduction was observed after a 6-h exposure (lane 4), as determined by densitometry readings. Ethidium bromide staining of the formaldehyde agarose gel was used to assure that comparable amounts of RNA were used for each experimental point (Fig. 1, middle). Also, the 1.4-kb IL-2 receptor mRNA showed little change in S-LB1





Figure 1. Regulation of GM-CSF mRNA levels in S-LB1 cells by 10^{-8} M 1,25(OH)₂D₃ (time course): lane 1, control (no 1,25(OH)₂D₃); lane 2, 0.5-h exposure; lane 3, 2-h exposure; lane 4, 6-h exposure; lane 5, 24-h exposure; lane 6, 48-h exposure. (Top) RNA blot of hybridization with a cDNA probe for GM-CSF. A single band could be detected at 0.9 kb which is consistent with GM-CSF mRNA. (Middle) Ethidium bromide staining of the 28S and 18S RNA of the formaldehyde agarose gel of the RNA blot shown in the upper panels. (Bottom) The Northern blot was rehybridized with a cDNA probe for IL-2 receptor and the 1.4-kb IL-2 receptor (IL-2R) band is shown. Analyses were performed as described in Methods. Each lane contains 20 μ g cytoplasmic RNA.

cells cultured with 1,25(OH)₂D₃ (Fig. 1, bottom). We also determined whether 1,25(OH)₂D₃ might regulate the expression of the β -actin and p53 genes. The protooncogene p53 is often present in actively proliferating cells, but is undetectable or expressed at low levels in resting cells (29). The S-LB1 cells constitutively express the p53 gene. The 1,25(OH)₂D₃ (10^{-8} M for 48 h) reduced mRNA levels of β -actin and p53 by approximately twofold compared with untreated control samples (data not shown). These results suggest that 1,25(OH)₂D₃ regulates mRNA levels of different genes. The viability of S-LB1 cells was not affected at any of the experimental points, as determined by trypan blue exclusion.

Influence of protein synthesis on the regulation of GM-CSF by 1,25(OH)₂D₃ in S-LB1 cells (Fig. 2). To determine the role of new protein synthesis in the regulation of GM-CSF mRNA levels in S-LB1 cells with exposure to 1,25(OH)₂D₃, the cells were pretreated for 45 min with 20 μ g/ml cycloheximide (a protein synthesis inhibitor) and then exposed to 10^{-8} M 1,25(OH)₂D₃ for 6 h. As a control, S-LB1 cells were cultured with cycloheximide alone (20 μ g/ml for 6.5 h). Cycloheximide blocked > 85% of protein synthesis in S-LB1 cells as measured by [35 S]methionine incorporation. As shown in Fig. 2, inhibition of new protein synthesis abolished the inhibitory effect of 1,25(OH)₂D₃ on GM-CSF mRNA accumulation (lane 4). The



1,25(OH)₂D₃ alone; lane 3, S-LB1 cells treated for 6.5 h with cycloheximide alone; lane 4, RNA from S-LB1 cells after treatment with cycloheximide for an initial 30 min and exposure to 1,25(OH)₂D₃ for an additional 6 h. Analyses were performed as described in Methods.

cycloheximide alone increased GM-CSF mRNA levels by approximately twofold (lane 3) compared with the untreated control sample (lane 1).

Level of regulation of GM-CSF by 1,25(OH)₂D₃ in S-LB1 cells (Figs. 3–5). The 1,25(OH)₂D₃ might regulate expression of GM-CSF at either the transcriptional or posttranscriptional level. In vitro transcriptional run-on assays were performed to determine if the regulation was at the level of transcription (Fig. 3). In this assay in vitro transcripts are generated by elongation of previously initiated RNA chains in the presence of [α^{32} P]UTP. As demonstrated in Fig. 3, levels of GM-CSF transcripts did not change in S-LB1 cells that were treated with 10⁻⁸ M 1,25(OH)₂D₃ for either 6 or 48 h compared with the untreated control sample (lane 1 in each panel of Fig. 3). Also, almost no change in the rate of β -actin transcripts was observed (lane 2 of each panel). Furthermore, nonspecific hybridization to β -globin DNA did not occur (lane 3). No nonspecific hybridization to plasmid DNA was seen (Southern blot contained both the eukaryotic inserts [GM-CSF, β -actin, and β -globin] and the restriction-digested, linearized plas-




Figure 3. Transcriptional run-on analysis of GM-CSF in isolated nuclei of S-LB1 cells untreated or treated with (10⁻⁸ M) 1,25(OH)₂D₃ for 0, 6, and 48 h. Analysis was performed as described in Methods. Autoradiograms show hybridization of ³²P-labeled transcripts to GM-CSF DNA (lanes 1, 0.9-kb bands); β -actin DNA, positive control (lanes 2, 0.7-kb bands), and β -globin DNA, negative control (lane 3). The DNA inserts (10 μ g) were size-separated from their plasmid vectors by electrophoresis on an agarose gel and transferred to a nylon membrane filter. Autoradiogram was exposed to film for 3.5 d.

Figure 2. Influence of the inhibition of new protein synthesis on the action of 10⁻⁸ M 1,25(OH)₂D₃ on GM-CSF mRNA levels in S-LB1 cells. New protein synthesis was blocked by 20 μ g/ml cycloheximide. Cytoplasmic RNA (20 μ g/lane) was extracted and analyzed by RNA blot technique using a cDNA probe for GM-CSF. Lane 1, control S-LB1 cells (no cycloheximide, no 1,25(OH)₂D₃); lane 2, S-LB1 cells exposed for 6 h to

midis). Similar results were observed in another run-on transcriptional assay (data not shown).

Posttranscriptional regulation was examined by determining changes in GM-CSF mRNA levels induced by 10⁻⁸ M 1,25(OH)₂D₃ when transcription was blocked by 5 μ g/ml actinomycin D. Actinomycin D blocked > 95% of transcription in S-LB1 cells as measured by [¹⁴C]uridine incorporation. Initially, the *t*_{1/2} of GM-CSF mRNA was determined in the presence of actinomycin D alone (Fig. 4 A, top). The GM-CSF mRNA had a *t*_{1/2} of 4 h. The *t*_{1/2} of GM-CSF mRNA was reexamined when transcription was blocked by actinomycin D and the cells were exposed simultaneously to 1,25(OH)₂D₃ (Fig. 4 B, top). Addition of 1,25(OH)₂D₃ to these cells resulted in a rapid and profound decrease of levels of GM-CSF mRNA; the *t*_{1/2} of GM-CSF mRNA under these conditions was < 30 min. Ethidium bromide staining of the formaldehyde agarose gel was used to assure that similar amounts of RNA were used (Fig. 4 B, bottom). These results suggest that 1,25(OH)₂D₃ regulates the expression of GM-CSF at the posttranscriptional level. Fig. 5 summarizes the densitometry readings of the autoradiograms shown in Figs. 1 and 4, A and B.

Discussion

The secosteroid 1,25(OH)₂D₃, which is the most active metabolite of vitamin D₃, effectively reduces the expression of the




Figure 4. Posttranscriptional analysis of GM-CSF mRNA regulation by 1,25(OH)₂D₃. (A, top) Determination of the *t*_{1/2} of GM-CSF mRNA in S-LB1 cells by RNA blot technique. S-LB1 cells were exposed for various durations to 5 μ g/ml actinomycin D and the cytoplasmic RNA (20 μ g/lane) of these cells were hybridized with a GM-CSF cDNA probe. Lane 1, control (no actinomycin D); lane 2, 0.5-h exposure; lane 3, 2-h exposure; lane 4, 6-h exposure; and lane 5, 10-h exposure. The *t*_{1/2} of GM-CSF was determined by the decay of GM-CSF mRNA levels. (Bottom) Ethidium bromide stain of the 28S and 18S RNA on the formaldehyde agarose gel. (B, top) Determination of the *t*_{1/2} of GM-CSF mRNA in the presence of 1,25(OH)₂D₃ when transcription was blocked by actinomycin D. S-LB1 cells were exposed to 10⁻⁸ M 1,25(OH)₂D₃ and 5 μ g/ml actinomycin D. Cytoplasmic RNA (20 μ g/lane) was extracted and analyzed by Northern blot technique as described in Methods. Lane 1, control RNA of S-LB1 cells (no 1,25(OH)₂D₃, no actinomycin D); lane 2, 0.5-h exposure to both agents; lane 3, 2-h exposure; and lane 4, 6-h exposure to both agents, respectively. (Bottom) Ethidium bromide staining of 28S and 18S RNA on the formaldehyde agarose gel of the RNA blot shown in the top panel.




Figure 5. $t_{1/2}$ of GM-CSF mRNAs from S-LB1 cells treated with either 1,25(OH)₂D₃ (●), actinomycin D alone (▲), or with both agents simultaneously (○). Autoradiograms shown in Figs. 1 and 4 A and B were quantitated by densitometry using the control samples (no 1,25(OH)₂D₃, no actinomycin) as a reference for 100% GM-CSF mRNA accumulation.

hematopoietic growth factor GM-CSF in both normal human T lymphocytes and the HTLV-1 immortalized T cell line S-LB1 at both the levels of mRNA and protein (13). In the present paper we extended this observation by studying at least in part the mechanism of regulation of GM-CSF gene expression by 1,25(OH)₂D₃. Exposure of S-LB1 cells to 10⁻⁸ M 1,25(OH)₂D₃ resulted in a marked decrease of GM-CSF mRNA accumulation with a 50 and 90% reduction of the mRNA at 6 and 48 h, respectively, as compared with the untreated control sample (Fig. 1, top). Cell viability in the cells cultured with 1,25(OH)₂D₃ were the same as control cells (> 95% viable by trypan blue staining). We recently showed that inhibition of total RNA by 1,25(OH)₂D₃, as measured by [¹⁴C]uridine incorporation, was less pronounced and less rapid than the decrease of GM-CSF mRNA in S-LB1 cells (13). Furthermore, we found that 1,25(OH)₂D₃ did not decrease levels of the 1.4-kb band of the IL-2 receptor mRNA (13). In the present study, 1,25(OH)₂D₃ (10⁻⁸ M for 48 h) reduced mRNA levels of β -actin and p53 by approximately twofold, which suggests that 1,25(OH)₂D₃ can affect mRNA levels of several genes in S-LB1 cells.

Our study further showed that inhibition of new protein synthesis by cycloheximide abolished the effect of 1,25(OH)₂D₃, which indicates that the action of 1,25(OH)₂D₃ on GM-CSF expression is dependent on new protein synthesis. Cycloheximide alone increased GM-CSF mRNA levels twofold. This suggests the presence of a protein that destabilizes GM-CSF mRNA in S-LB1 cells, or suggests that degradation of mRNA requires its active translation (30). A similar superinduction by cycloheximide has been found in other transiently expressed genes such as *c-myc* (31–33).

The $t_{1/2}$ of GM-CSF mRNA was ~4 h, which demonstrates that GM-CSF is a moderately long-lived mRNA in S-LB1 cells. Other investigators recently showed that GM-CSF is a short-lived mRNA ($t_{1/2}$ ~30 min) in PHA-stimulated peripheral blood T lymphocytes, whereas in phorbol-diester-induced peripheral blood T lymphocytes the $t_{1/2}$ was > 2 h (34). One explanation for this discrepancy might be the different modes of stimulation of the T lymphocytes that produce

GM-CSF. The S-LB1 cells are HTLV-1 immortalized T lymphocytes and constitutively express GM-CSF, whereas normal T lymphocytes produce GM-CSF only upon mitogenic stimulation.

Transcriptional and posttranscriptional mechanisms regulate the expression of genes in eukaryotic cells (14). Little is known about the exact mechanism by which the secosteroid 1,25(OH)₂D₃ regulates expression of eukaryotic genes. Studies showed that a variety of cells, including hematopoietic cells, contain specific receptors for 1,25(OH)₂D₃ (35). Very recent studies showed that 1,25(OH)₂D₃ transcriptionally regulated *c-myc* expression in the promyelocytic HL-60 leukemia cells (36). Our recent study clearly demonstrated that the action of 1,25(OH)₂D₃ on the expression of GM-CSF in human T lymphocytes was mediated by a specific receptor for this steroid (13). In the case of glucocorticoids, transcriptional activation of gene expression was found to be mediated by an interaction of hormone-receptor complexes with specific DNA sequences, and negative regulation might be likely to be affected by similar hormone-receptor complex–DNA interactions (for review, see reference 37). In a parallel fashion the 1,25(OH)₂D₃ receptor complex might interact with specific sequences of the GM-CSF gene, and thus transcriptionally regulate the expression of GM-CSF. However, our in vitro nuclear run-on assay revealed that 1,25(OH)₂D₃ did not alter the rate of GM-CSF transcription in S-LB1 cells (Fig. 3). By contrast, a sharp decrease of GM-CSF mRNA levels occurred in the S-LB1 cells exposed to 1,25(OH)₂D₃ when transcription and therefore new mRNA production of these cells were blocked by actinomycin D (Figs. 4 B and 5). These results suggest that 1,25(OH)₂D₃ posttranscriptionally regulates the expression of GM-CSF by influencing the stability of mRNA. Of note, but unexplained, is that GM-CSF mRNA concentrations decreased in S-LB1 in a biphasic manner after exposure of the cells to either actinomycin D, 1,25(OH)₂D₃, or most prominently actinomycin D plus 1,25(OH)₂D₃.

Several other studies have found that GM-CSF mRNA levels can be regulated posttranscriptionally by exposure of lymphocytes to 12-O-tetradecanoylphorbol 13-acetate (34) and exposure of macrophages to LPS and several other agents (38). Furthermore, GM-CSF mRNA as well as a variety of other lymphokines, including IL-2 and -3 and lymphocytotoxin, have conservation of adenosine-thymidine-rich sequences in the 3' untranslated region of their genes (34). Altering these regions markedly prolongs the $t_{1/2}$ of GM-CSF mRNA (34). Perhaps 1,25(OH)₂D₃ posttranscriptionally modulates GM-CSF by a direct or indirect effect on adenosine-uridine-rich sequences in the 3' untranslated GM-CSF mRNA. Another possible mechanism by which 1,25(OH)₂D₃ might regulate the gene expression of GM-CSF at the posttranscriptional level is by an accelerated degradation of GM-CSF mRNA such as by the (2'–5') A synthetase/RNA L pathway (for review, see reference 39).

Acknowledgments

We would like to thank Suzanne Bookstaver and Regina Simon for their excellent secretarial help, and Dr. Milan Uskokovic (Hoffmann-La Roche, Nutley, NJ) for providing 1,25(OH)₂D₃.

This work was supported by U. S. Public Health Service grants CA-26038, CA-32737, CA-33936, CA-30512, and CA-32428; the Dr. Murray Geisler Memorial Fund and the Louis Fagin Leukemia Research Foundation (H. P. Koeffler); grant AM-14, 750-014 (H. P.

Koeffler and A. W. Norman); and the Swiss and Bernese Cancer Liges (A. Tobler).

References

1. Cantrel, M. A., D. Anderson, D. P. Cerretti, V. Price, K. McKereghan, R. J. Tushinski, D. Y. Mochizuki, A. Larsen, K. Grabstein, S. Gillis, and D. Cosman. 1985. Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor. *Proc. Natl. Acad. Sci. USA* 82:6250-6254.
2. Wong, G. G., J. A. S. Witek, P. A. Temple, K. M. Wilkens, A. C. Leary, D. P. Luxenberg, S. S. Jones, E. L. Brown, R. M. Kay, E. C. Orr, C. H. Shoemaker, D. W. Golde, R. J. Kaufman, R. M. Hewick, E. A. Wang, and S. C. Clark. 1985. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. *Science (Wash. DC)* 228:810-815.
3. Munker, R., J. Gasson, M. Ogawa, and H. P. Koeffler. 1986. Recombinant human TNF induces production of granulocyte-macrophage colony-stimulating factor. *Nature (Lond.)* 323:79-82.
4. Bagby, G. C., Jr., C. A. Dinarello, P. Wallace, C. Wagner, S. Hefeneider, and E. McGall. 1986. Interleukin-1 stimulates granulocyte-macrophage colony-stimulating activity release by vascular endothelial cells. *J. Clin. Invest.* 78:1316-1323.
5. Tomonaga, M., D. W. Golde, and J. C. Gasson. 1986. Biosynthetic (recombinant) human granulocyte-macrophage colony-stimulating factor: effect on normal bone marrow and leukemic cell lines. *Blood* 67:31-36.
6. Sieff, C. A., S. G. Emerson, R. E. Donahue, D. G. Nathan, E. A. Wang, G. G. Wong, and S. C. Clark. 1985. Recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin. *Science (Wash. DC)* 230:1171-1173.
7. Gasson, J. C., R. H. Weissbart, S. E. Kaufman, S. C. Clark, R. M. Hewick, G. G. Wong, and D. W. Golde. 1984. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. *Science (Wash. DC)* 226:1339-1342.
8. Weissbart, R. H., D. W. Golde, S. C. Clark, G. G. Wong, and J. C. Gasson. 1985. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. *Nature (Lond.)* 314:361-363.
9. Bell, N. H. 1985. Vitamin D-endocrine system. *J. Clin. Invest.* 76:1-6.
10. Manolagas, S. C., and L. J. Deftos. 1984. The vitamin D endocrine system and the hematolymphopoietic tissue. *Ann. Intern. Med.* 100:144-146.
11. Adams, J. S., and M. A. Gacad. 1985. Characterization of 1 α -hydroxylation of vitamin D₃ sterols by cultured alveolar macrophages from patients with sarcoidosis. *J. Exp. Med.* 161:755-765.
12. Koeffler, H. P., H. Reichel, J. E. Bishop, and A. W. Norman. 1985. γ -interferon stimulates production of 1,25-dihydroxyvitamin D₃ by normal human macrophages. *Biochem. Biophys. Res. Commun.* 127:596-603.
13. Tobler, A., J. Gasson, H. Reichel, A. W. Norman, and H. P. Koeffler. 1987. Granulocyte-macrophage colony-stimulating factor: sensitive and receptor-mediated regulation by 1,25-dihydroxyvitamin D₃ in normal human peripheral blood lymphocytes. *J. Clin. Invest.* 79:1700-1705.
14. Darnell, J. E., Jr. 1982. Variety in the level of gene control in eukaryotic cells. *Nature (Lond.)* 297:365-371.
15. Dani, C., N. Mehti, M. Piechaczyk, B. Lebleu, P. Jantour, and J. M. Blanchard. 1985. Increased rate of degradation of c-myc mRNA in interferon-treated Daudi cells. *Proc. Natl. Acad. Sci. USA* 82:4896-4899.
16. Knight, E., Jr., E. D. Anton, D. Fahey, B. K. Friedland, and J. Jonak. 1985. Interferon regulates c-myc expression in Daudi cells at the post-transcriptional level. *Proc. Natl. Acad. Sci. USA* 82:1152-1154.
17. Bentley, D. L., and M. Groudine. 1986. A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. *Nature (Lond.)* 321:702-706.
18. Tobler, A., C. Miller, D. Johnston, and H. P. Koeffler. Recombinant human tumor necrosis factor α regulates c-myc expression in HL-60 cells at the level of transcription. *Blood* 70:2000-2051.
19. Krönke, M., C. Schlüter, and K. Pfizenmaier. 1987. Tumor necrosis factor inhibits c-myc expression in HL-60 cells at the level of transcription. *Proc. Natl. Acad. Sci. USA* 84:469-473.
20. Yordan, A., and A. Kimchi. 1986. Tumor necrosis factor reduces c-myc and cooperates with interferon- γ in Hela cells. *Science (Wash. DC)* 234:1419-1421.
21. Koeffler, H. P., I. S. Y. Chen, and D. W. Golde. 1984. Characterization of a novel HTLV-infected cell line. *Blood* 64:482-490.
22. Harlow, E., N. M. Williamson, R. Ralston, D. M. Helfman, and T. E. Adams. 1985. Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. *Mol. Cell. Biol.* 5:1601-1610.
23. Ponte, P., P. Gunning, H. Blau, and L. Kedes. 1983. Human actin genes are single copy for α -skeletal and α -cardiac actin but multicopy for β - and γ -cytoskeletal genes: 3' untranslated regions are isotype specific but are conserved in evolution. *Mol. Cell. Biol.* 3:1783-1791.
24. Miller, C. W., K. Young, D. Dumenil, P. B. Alter, J. A. Schofield, and A. Bank. 1984. Specific globin mRNAs in human erythroleukemia (K562) cells. *Blood* 63:195-200.
25. Feinberg, A. P., and B. Vogelstein. 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. *Anal. Biochem.* 132:6-13.
26. Clemens, M. J. 1984. Purification of eukaryotic mRNA. In *Transcription and Translation*. B. D. Hames and S. J. Higgins, editors. IRL Press, Washington. 211-220.
27. Goldberg, D. A. 1980. Isolation and partial characterization of the *Drosophila* alcohol dehydrogenase gene. *Proc. Natl. Acad. Sci. USA* 77:5794-5798.
28. Groudine, M., M. Peretz, and H. Weintraub. 1981. Transcriptional regulation of hemoglobin switching in chicken embryos. *Mol. Cell. Biol.* 3:281-288.
29. Milner, J., and S. Milner. 1981. SV-40-53 K antigen: a possible role for p53 in normal cells. *Virology* 112:785-788.
30. Linial, M., N. Gunderson, and M. Groudine. 1985. Enhanced transcription of c-myc in Bursal lymphoma cells requires continuous protein synthesis. *Science (Wash. DC)* 230:1126-1132.
31. Dani, C., J. M. Blanchard, M. Piechaczyk, E. Sabouty, L. Mary, and P. Jantour. 1984. Extreme instability of c-myc mRNA in normal and transformed human cells. *Proc. Natl. Acad. Sci. USA* 81:7046-7050.
32. Greenberg, M. E., A. L. Hermanowsky, and E. B. Ziff. 1986. Effect of protein synthesis inhibitors on growth factor activation of c-fos, c-myc, and actin gene transcription. *Mol. Cell. Biol.* 6:1050-1057.
33. Kelly, K., B. H. Cochran, C. D. Stiles, and P. Leder. 1983. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. *Cell* 35:603-610.
34. Shaw, G., and R. Kamen. 1986. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. *Cell* 46:659-667.
35. Provvedini, D. M., C. D. Tsoukas, L. J. Deftos, and S. C. Manolagas. 1983. 1,25-dihydroxyvitamin D₃ receptors in human leukocytes. *Science (Wash. DC)* 221:1181-1183.
36. Simpson, R. U., T. Hsu, D. A. Begley, B. S. Mitchell, and B. N. Alizadeh. 1987. Transcriptional regulation of the c-myc proto-oncogene by 1,25-dihydroxyvitamin D₃ in HL-60 promyelocytic leukemia cells. *J. Biol. Chem.* 262:4104-4108.
37. Yamamoto, K. R. 1985. Steroid receptor-regulated transcription of specific genes and gene networks. *Annu. Rev. Genet.* 19:209-252.
38. Thorens, B., T. T. Mermod, and P. Vassalli. 1987. Phagocytosis and inflammatory stimuli induce GM-CSF mRNA in macrophages through posttranscriptional regulation. *Cell* 48:671-679.
39. Lenyel, P. 1982. Biochemistry of interferons and their related actions. *Annu. Rev. Biochem.* 51:251-282.